Propan-2-yl 3-(4-hydroxyphenyl)-2-(methoxymethoxy)propanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Propan-2-yl 3-(4-hydroxyphenyl)-2-(methoxymethoxy)propanoate
• 化学式: C₁₄H₂₀O₅
• 分子量: 268.3
• InChiKey: PYCADNVKWQMKNZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  19
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• 3-Aryl-A-oxy substituted propanoic acids and a process for their preparation
  申请人：——

  公开号：US20040248849A1

  公开（公告）日：2004-12-09

  The present invention relates to novel antidiabetic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel 3-aryl-&agr;-oxy substituted propanoic acids of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs and pharmaceutically acceptable compositions containing them. Formula (I) where R 1 represents t-butyldimethyl silyl, trimethyl silyl or alkoxyalkyl group; R 2 represents hydrogen or substituted or unsubstituted (C 1 -C 6 )alkyl group. 1

  本发明涉及新型抗糖尿病化合物及其衍生物、类似物、互变异构体、立体异构体、多晶形式和药学上可接受的含有它们的组合物。更具体地，本发明涉及一般式（I）的新型3-芳基-&agr;-氧基取代的丙酸类化合物，其衍生物、类似物、互变异构体、立体异构体、多晶形式和药学上可接受的含有它们的组合物。其中，式（I）中，R1表示叔丁基二甲基硅基、三甲基硅基或烷氧基烷基；R2表示氢或取代或未取代的（C1-C6）烷基。
• [EN] 3-ARYL- DOLLAR G(a)-OXY SUBSTITUTED PROPANOIC ACIDS AND A PROCESS FOR THEIR PREPARATION<br/>[FR] ACIDES PROPANOIQUES SUBSTITUES PAR 3-ARYL- DOLLAR G(a)-OXY ET LEUR PROCEDE DE PREPARATION
  申请人：REDDY RESEARCH FOUNDATION

  公开号：WO2003002575A1

  公开（公告）日：2003-01-09

  The present invention relates to novel antidiabetic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel 3-aryl-α-oxy substituted propanoic acids of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs and pharmaceutically acceptable compositions containing them. Formula (I) where R1 represents t-butyldimethyl silyl, trimethyl silyl or alkoxyalkyl group; R2 represents hydrogen or substituted or unsubstituted (C¿1?-C6)alkyl group.